MapLight (MPLT) CMO sells 50K shares, retains 350K-share stake

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

MapLight Therapeutics Chief Medical Officer Erin Pennock Foff sold 50,280 shares of Voting Common Stock in open-market trades. The sales occurred on May 4–6, 2026 at prices generally in the high‑$20s to low‑$30s per share.

The transactions were made under a Rule 10b5-1 trading plan adopted on December 29, 2025, indicating they were pre‑scheduled. After these sales, Foff directly holds 350,497 shares of MapLight Therapeutics common stock.

Insights

Planned, open-market sales by the CMO reduce holdings but appear routine.

Erin Pennock Foff, Chief Medical Officer of MapLight Therapeutics, sold a total of 50,280 shares of Voting Common Stock in eight open‑market transactions between May 4 and May 6, 2026. Reported prices range from roughly the high‑$20s to low‑$30s per share.

The filing states these sales were executed under a Rule 10b5-1 trading plan adopted on December 29, 2025, meaning they were pre‑scheduled rather than timed opportunistically. Following the sales, she directly owns 350,497 shares, indicating a continuing, substantial equity stake.

The weighted‑average price disclosures and price ranges in the footnotes show that each line aggregates multiple trades, a common practice for larger liquidity events. Overall, the pattern is a net‑sell but, given the remaining position and pre‑planned nature, it appears as routine portfolio management rather than a thesis‑changing move.

Insider Trade Summary 10b5-1

Net Seller: 50,280 shares ($1,427,594)

Net Sell 8 txns

Insider Foff Erin Pennock

Role Chief Medical Officer

Sold 50,280 shs ($1.43M)

Type	Security	Shares	Price	Value
Sale	Voting Common Stock	8,152	$28.04	$229K
Sale	Voting Common Stock	15,900	$29.13	$463K
Sale	Voting Common Stock	9,645	$28.12	$271K
Sale	Voting Common Stock	931	$29.00	$27K
Sale	Voting Common Stock	9,180	$27.50	$252K
Sale	Voting Common Stock	5,460	$28.37	$155K
Sale	Voting Common Stock	312	$29.56	$9K
Sale	Voting Common Stock	700	$30.08	$21K

Holdings After Transaction: Voting Common Stock — 366,397 shares (Direct, null)

Footnotes (1)

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.84 to $27.835 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.845 to $28.73 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.9669 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.755 to $28.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.80 to $29.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.675 to $28.6587 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.71 to $29.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 50,280 shares Post-transaction holdings: 350,497 shares Highest reported sale price: $30.55 per share +3 more

6 metrics

Shares sold 50,280 shares Total Voting Common Stock sold in this Form 4

Post-transaction holdings 350,497 shares Shares of Voting Common Stock held after sales

Highest reported sale price $30.55 per share Upper end of one weighted-average price range

Lowest reported sale price $26.84 per share Lower end of one weighted-average price range

Number of sale transactions 8 transactions Non-derivative open-market sales reported

Trading plan adoption date December 29, 2025 Date CMO adopted Rule 10b5-1 trading plan

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, Voting Common Stock

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Voting Common Stock financial

""security_title": "Voting Common Stock""

Form 4 Insider Transactions: What Each Field Means →

05/06/2026 - 05:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Foff Erin Pennock

(Last)

(First)

(Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY

CALIFORNIA

94063

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Voting Common Stock	05/04/2026		S⁽¹⁾		9,180	D	$27.5⁽²⁾	391,597	D
Voting Common Stock	05/04/2026		S⁽¹⁾		5,460	D	$28.37⁽³⁾	386,137	D
Voting Common Stock	05/04/2026		S⁽¹⁾		312	D	$29.56⁽⁴⁾	385,825	D
Voting Common Stock	05/04/2026		S⁽¹⁾		700	D	$30.08⁽⁵⁾	385,125	D
Voting Common Stock	05/05/2026		S⁽¹⁾		9,645	D	$28.12⁽⁶⁾	375,480	D
Voting Common Stock	05/05/2026		S⁽¹⁾		931	D	$29⁽⁷⁾	374,549	D
Voting Common Stock	05/06/2026		S⁽¹⁾		8,152	D	$28.04⁽⁸⁾	366,397	D
Voting Common Stock	05/06/2026		S⁽¹⁾		15,900	D	$29.13⁽⁹⁾	350,497	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.84 to $27.835 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.845 to $28.73 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.9669 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.755 to $28.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.80 to $29.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.675 to $28.6587 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.71 to $29.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did MapLight Therapeutics (MPLT) disclose about its Chief Medical Officer’s recent stock sales?

MapLight Therapeutics reported that Chief Medical Officer Erin Pennock Foff sold 50,280 shares of Voting Common Stock in open-market trades from May 4–6, 2026. The sales were executed at prices generally in the high-$20s to low-$30s per share.

Were the MapLight Therapeutics (MPLT) insider sales made under a Rule 10b5-1 trading plan?

Yes. The filing states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Erin Pennock Foff on December 29, 2025. Such plans pre-schedule trades, indicating the timing was arranged in advance rather than decided spontaneously.

How many MapLight Therapeutics (MPLT) shares does the CMO hold after these Form 4 sales?

After the reported sales, Chief Medical Officer Erin Pennock Foff directly owns 350,497 shares of MapLight Therapeutics Voting Common Stock. This post-transaction balance reflects her remaining equity stake following the 50,280 shares sold in the disclosed trades.

Over what dates did the MapLight Therapeutics (MPLT) insider transactions occur and at what prices?

The insider transactions occurred on May 4, 5, and 6, 2026. Weighted-average sale prices reported for individual trades range roughly from about $26.84 to $30.55 per share, with each price representing multiple underlying executions within specified ranges.

What type of transactions were reported in the MapLight Therapeutics (MPLT) Form 4 filing?

All reported transactions were sales of Voting Common Stock coded as open-market or private sale (transaction code S). There were eight separate entries, each representing non-derivative common stock sold, with no related option exercises or derivative transactions disclosed.